Indications for cholesterol-lowering medication: comparison of risk-assessment methods (Q40825995)

24 September 2017

title

Indications for cholesterol-lowering medication: comparison of risk-assessment methods (English)

1 reference

24 September 2017

P N Durrington

1

1 reference

24 September 2017

H Prais

2

1 reference

24 September 2017

D Bhatnagar

3

1 reference

24 September 2017

M France

4

1 reference

24 September 2017

V Crowley

5

1 reference

24 September 2017

J Khan

6

1 reference

24 September 2017

J Morgan

7

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

24 September 2017

1 reference

24 September 2017

volume

353

1 reference

24 September 2017

issue

9149

1 reference

24 September 2017

page(s)

278-281

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

Cholesterol lowering and mortality: the importance of considering initial level of risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

Lipid-lowering for prevention of coronary heart disease: what policy now?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

Mismatch of coronary risk and treatment intensity under the national cholesterol education program guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

Screening for total cholesterol. Do the National Cholesterol Education Program's recommendations detect individuals at high risk of coronary heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

Cardiovascular disease risk profiles.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

A comparison of three methods of measuring serum high density lipoprotein cholesterol in diabetics and non-diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904027-6

7 January 2021

10.1016/S0140-6736(98)04027-6

Identifiers

DOI

1 reference

24 September 2017

1 reference